Jason Amello - Candel Therapeutics Chief Officer
| CADL Stock | USD 4.61 0.44 8.71% |
Insider
Jason Amello is Chief Officer of Candel Therapeutics
| Age | 56 |
| Address | 117 Kendrick Street, Needham, MA, United States, 02494 |
| Phone | 617 916 5445 |
| Web | https://www.candeltx.com |
Jason Amello Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jason Amello against Candel Therapeutics stock is an integral part of due diligence when investing in Candel Therapeutics. Jason Amello insider activity provides valuable insight into whether Candel Therapeutics is net buyers or sellers over its current business cycle. Note, Candel Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Candel Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jason Amello over a year ago Acquisition by Jason Amello of 90000 shares of Candel Therapeutics subject to Rule 16b-3 |
Candel Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5231) % which means that it has lost $0.5231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.8068) %, meaning that it created substantial loss on money invested by shareholders. Candel Therapeutics' management efficiency ratios could be used to measure how well Candel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.97. Return On Capital Employed is expected to rise to -1.35 this year. At this time, Candel Therapeutics' Debt To Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0 this year, although the value of Non Currrent Assets Other will most likely fall to about 312.6 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| , MBA | Molecular Partners AG | 51 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| MD FACP | AN2 Therapeutics | 76 | |
| Walt Esq | Indaptus Therapeutics | 63 | |
| Paul MD | AN2 Therapeutics | 54 | |
| LLM JD | Rezolute | 63 | |
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| CPA CPA | Acurx Pharmaceuticals LLC | 57 | |
| Niels Svenstrup | PepGen | 54 | |
| Wim Souverijns | Pharvaris BV | 53 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Robyn Sweinhart | Rezolute | N/A | |
| Guizhong Liu | Adagene | 53 | |
| Antony CPA | Forte Biosciences | 57 | |
Management Performance
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.52 |
Candel Therapeutics Leadership Team
Elected by the shareholders, the Candel Therapeutics' board of directors comprises two types of representatives: Candel Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Candel. The board's role is to monitor Candel Therapeutics' management team and ensure that shareholders' interests are well served. Candel Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Candel Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Schoch, Principal CFO | ||
| Francesca MD, Chief Officer | ||
| FOCIS MD, CEO President | ||
| LLM JD, Chief Officer | ||
| Nathan Caffo, Chief Officer | ||
| MS MD, Chief Officer | ||
| FMEDSCI MD, CEO Pres | ||
| MD MS, Chief Officer | ||
| Jason Amello, Chief Officer | ||
| Inf MD, Founder Director | ||
| Carrie Cox, Special CEO | ||
| Seshu Tyagarajan, Chief Officer | ||
| Ileen Winick, Chief Officer |
Candel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Candel Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 166.39 M | ||||
| Shares Outstanding | 32.48 M | ||||
| Shares Owned By Insiders | 30.39 % | ||||
| Shares Owned By Institutions | 22.53 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Book | 30.41 X | ||||
| Price To Sales | 436.42 X | ||||
| Revenue | 31 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.